“This is a highly significant achievement for Mucocort AB. Receiving our first approved patent in the U.S. validates both the medical utility and innovation behind our technology and the long-term commercial potential of M045A. The United States is one of the world’s most important healthcare markets, and this approval gives us a strong strategic foundation for a future market launch of our product,” says Jean Lycke, Project Manager at Mucocort AB.
Affecting millions of people globally
Mucocort AB is developing M045A, a biodegradable mucoadhesive patch designed to provide rapid pain relief and accelerated healing of oral aphthous ulcers. The product addresses a widespread condition affecting millions of people globally.
The newly approved U.S. patent protects Mucocort’s proprietary technology and strengthens the company’s position ahead of future partnering, licensing, and commercialization discussions.
Strengthens Mucocort’s IP portfolio
Professor Thomas Hedner, Board Member at Mucocort AB, comments:
“Obtaining patent protection in the United States is an important milestone for any innovation-driven company. This approval significantly strengthens Mucocort’s intellectual property portfolio and supports the company’s future international expansion.”
The company continues to pursue additional patent applications and intellectual property protection in strategic international markets.
Mucocort is based at Umeå Biotech Incubator and receives business support from UBI.
For more information, please contact:
Jean Lycke, Project Manager, Mucocort AB
Email: jl@emerentiagruppen.com
Mobile: +46 70 277 15 11
About Mucocort AB
Mucocort AB is a Swedish MedTech company focused on developing innovative treatments for conditions affecting the oral mucosa. The company’s lead product candidate, M045A, is a next-generation mucoadhesive patch developed for the treatment of recurrent aphthous stomatitis (RAS), commonly known as mouth ulcers.